Navigation Links
Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco

Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia... -- SAN FRANCISCO, October 13, 2010 /PRNewswire-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Publishing & Information Services, Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Trade Show News Click to view news release full screen  

Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco


SAN FRANCISCO, October 13, 2010 /PRNewswire-FirstCall/ -- Elsevier Business Intelligence, publisher of PharmAsia News, IN VIVO and "The Pink Sheet," today announced the agenda for Windhover's 2nd PharmAsia Summit ( (Oct. 25-26). This year's Summit will bring top biopharma leaders from Asia and the U.S. to San Francisco to share what works and what doesn't in China, India, Japan and the Pacific Rim.

At the PharmAsia Summit, you'll hear Asia strategies and case studies from industry leading experts on dealmaking, commercial strategy, outsourcing, regulatory risks, IP protection, and pricing and reimbursement. Confirmed speakers include:

- Biogen Idec's Gunther Winkler, Senior VP Asia Pacific & Global Government Strategy - Merck's Ramesh Subrahmanian, Senior VP & President of Asia Pacific Human Health - Takeda Research Investment CEO Graeme Martin - Pfizer's Neil Gibson, CSO Oncology Research - Gilead's Clifford Samuel, VP International Access - Advinus Therapeutics CEO Rashmi Barbhaiya - Onyx CEO Anthony Coles - S*Bio CEO Jan-Anders Karlsson - Piramal Life Sciences Managing Director Somesh Sharma - IMS Asia Pacific VP Jan Willem Eleveld - Piper Jaffrey China Healthcare Analyst Hongbo Lu Plus, you'll have a rare opportunity to speak with top Asia regulators, including: - U.S. FDA China Office Director Chris Hickey - U.S. FDA India Office Director Bruce Ross - Shanghai FDA Deputy Director General Yi Chengdong - Korea FDA's Hong Soon-Wook, Director Pharmaceutical Safety Policy

"PharmAsia Summit is a rare opportunity for U.S. biopharma execs to gain an insider's perspective on the most important developments in China, India and Japan without having to cross the Pacific," said Gerry Stoia, president of Elsevier Business Intelligence. "Given the increasing importance of markets like China and India to the biopharma industry, we are honored to host this distinguished group in San Francisco, and hope the Summit will contribute to the dialogue between U.S. and Asia biopharma leaders."

Attendees will in addition learn the latest on China healthcare reform, U.S. FDA actions in China and India, case studies on Japanese dealmaking with U.S. biotechs, novel Asia investment strategies, tips for launching innovative therapies in India and China, opportunities for pre-competitive collaboration that will help de-risk R&D, and finding the right partner in Asia.

Moreover, attendees will catch up on the latest Asian market trends and data from IMS Health, which sees China becoming the third largest pharma market in 2011 and predicts explosive growth in other hot Asia markets like India and Korea.

For further information:

About Windhover Conferences and Elsevier Business Intelligence

Windhover Conferences is an Elsevier Business Intelligence company, the leading provider of business intelligence and analysis to senior executives in the medical device, pharmaceutical, and biotechnology industries. Publishers of "The Pink Sheet," ( PharmAsia News ( , "The Tan Sheet" (http://thetansheet), IN VIVO: The Business & Medicine Report (, Start-Up: Emerging Medical Ventures (, and The RPM Report: Regulation - Policy - Market Access (, Elsevier and Windhover also host a variety of industry meetings and webinars in both medical device and pharma/biotech, and produce a wide array of market research reports. For more on the companies' products and services, please visit

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet ( and Cell 9, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect (, SciVerse Scopus (, Reaxys (, MD Consult ( and Nursing Consult (, which enhance the productivity of science and health professionals, and the SciVal suite ( and MEDai's Pinpoint Review (, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier ( employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contact Joshua L. Berlin Elsevier Business Intelligence Mobile: +1-301-538-3527

SOURCE Elsevier
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions
2. Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
3. PDL BioPharma Completes October 1 Special Dividend Payment
4. Genesis Biopharma Announces $700K Private Financing
5. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
6. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
7. Helix BioPharma Approved for NYSE Amex Listing
8. PDL BioPharma Provides Clarification Regarding Redemption of Its 2.75% Convertible Subordinated Notes
9. PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech
10. Reportlinker Adds Advances in Biopharmaceutical Technology in China
11. PDL BioPharma Announces Retirement of $61.6 Million of 2.75% Convertible Notes due August 2023 for Common Stock
Post Your Comments:
(Date:11/24/2015)... HILLS, N.J. (PRWEB) , ... November 24, 2015 , ... ... as the recipient of the 2016 USGA Green Section Award. Presented annually since 1961, ... golf through his or her work with turfgrass. , Clarke, of Iselin, ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended September 30, ... Canadian dollars and presented under International Financial Reporting ... ," said Andrew Rae , President ... iCo-008 are not only value enriching for this ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... This fall, ... at competitive events in five states to develop and pitch their BIG ideas to ... from each state are competing for votes to win the title of SAP's Teen ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
(Date:10/29/2015)... 2015  The J. Craig Venter Institute (JCVI) policy ... and Biosecurity: Lessons Learned and Options for the Future," ... Human Services guidance for synthetic biology providers has worked ... --> --> Synthetic biology promises ... to pose unique biosecurity threats. It now is easier ...
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
Breaking Biology News(10 mins):